About Us

SciencewerkeDX, a division of Sciencewerke Pte Ltd, works with market leading innovative diagnostic companies across multiple medical specialties to provide doctors, patients and their families with proprietary actionable genetic and molecular diagnostic tests that will allow for better medical management and treatment decisions, leading to a better quality of life.

SciencewerkeDX — Better tests. Better care. Better lives.

Sciencewerke Pte Ltd is a sales, marketing and distribution company focused on cutting-edge and emerging technologies in biomedical and life sciences. Founded in 2005, Sciencewerke is headquartered in Singapore and has offices in Malaysia and Indonesia. Over the years, we have established ourselves to become a niche provider of market-leading Genomics, Proteomics, Cellomics, Bio-imaging and Molecular Diagnostics solutions. www.sciencewerke.com.


Our Partners

Myriad Genetics, Inc.
Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients’ lives through the discovery and commercialization of transformative tests to assess a person’s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad’s molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual’s decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. www.myriad.com.

Ferrer inCode, S.L.
Ferrer inCode is the diagnostics division of Ferrer, the Spanish pharmaceutical company founded in 1959 and present in more than 90 countries, with 25 international affiliates. Ferrer inCode has co-developed and commercialized a number of groundbreaking genomic products to personalize the treatment of patients in the areas of cardiovascular disease, cardiac sudden death, thrombosis and nutrigenomics. www.ferrerincode.com.

Courtagen Life Sciences, Inc.
Courtagen is a privately-held life sciences and molecular information company that converts genomic data into actionable clinical information for the diagnosis of critical pediatric neurological and metabolic disorders. Specifically, Courtagen focuses on mitochondrial disorders, epilepsy, and intellectual disability, including autism spectrum disorders. Courtagen’s state-of-the-art Next-Generation Sequencing clinical laboratory integrates genotype, phenotype,and disease mechanism data using cloud-based computing and custom analytical methods to provide the most comprehensive results for clinicians, patients, and their families to better understand and treat their disease. www.courtagen.com.

Personalis, Inc.
Personalis provides researchers and clinicians accurate DNA sequencing and interpretation of human exomes and genomes. We support researchers engaging in case-control, family-based, or proband-only genomic studies of disease, pharmacogenomics, and cancer. Personalis ACE (Accuracy and Content Enhanced) Technology™ supplements a standard exome or genome, substantially increasing its medically-relevant coverage and accuracy. Personalis builds on this enhanced sequencing foundation with innovative algorithms and proprietary databases for alignment, variant calling, annotation, and analysis. Through this comprehensive approach, we provide genomic data and interpretation of the highest accuracy. www.personalis.com.

Personal Genome Diagnostics
Personal Genome Diagnostics (PGDx) is a provider of advanced technology solutions based on Next
Generation Sequencing (NGS) and related technologies for cancer genome analysis. PGDx has developed proprietary techniques that identify mutations found in a patient’s tumor through noninvasive testing of circulating tumor DNA. This allows for characterization of unique aspects of disease, such as detection and monitoring of cancer, as well as, identification of mechanisms of resistance to targeted therapy. PGDx is CLIA certified for high-complexity molecular testing using whole exome and targeted analysis approaches. Research and custom approaches include whole genome, exome, custom capture, targeted and plasma analysis. PGDx has developed and introduced a number of proprietary methods to study blood and tissue tumor samples, including methods for advanced bioinformatics analysis. www.mypersonalgenome.com